FDA Approves Avastin
Avastin Approved for treatment for Metastatic Colorectal Cancer
Avastin (bevacizumab) is a recombinant humanized monoclonal IgG1 antibody which in combination with intravenous 5-fluorouracil-based chemotherapy, is indicated for first- or second-line treatment of patients with metastatic carcinoma of the colon or rectum.Posted: February 2004
Related articles
- FDA Approves Genentech’s Avastin (bevacizumab) Plus Chemotherapy as a Treatment for Women With Advanced Ovarian Cancer Following Initial Surgery - June 13, 2018
- FDA Grants Genentech’s Avastin Full Approval for Most Aggressive Form of Brain Cancer - December 5, 2017
- FDA Approves Avastin (bevacizumab) Plus Chemotherapy for a Specific Type of Advanced Ovarian Cancer - December 6, 2016
- FDA Approves Avastin (bevacizumab) Plus Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer - November 14, 2014
- FDA Approves Avastin for Metastatic Cervical Cancer - August 14, 2014
- FDA Revokes Breast Cancer Indication for Avastin (bevacizumab) - November 18, 2011
- FDA Approves Avastin for the Most Common Type of Kidney Cancer - August 3, 2009
- FDA Grants Accelerated Approval of Avastin for Brain Cancer (Glioblastoma) That Has Progressed Following Prior Therapy - May 6, 2009
- FDA Grants Accelerated Approval of Avastin in Combination With Paclitaxel Chemotherapy for First-Line Treatment of Advanced HER2-Negative Breast Cancer - February 25, 2008
- FDA Approves Avastin in Combination With Chemotherapy for First-Line Treatment of Most Common Type of Lung Cancer - October 11, 2006
- Avastin Filed in US for Treatment of Most Common Form of Lung Cancer - April 12, 2006
Avastin (bevacizumab) FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.